📊 HNGE Key Takeaways
Is Hinge Health, Inc. (HNGE) a Good Investment?
Hinge Health demonstrates exceptional revenue growth of 50.6% YoY paired with world-class operational metrics, including 84.6% gross margins and robust free cash flow generation of $43M (23.6% FCF margin), all supported by a fortress balance sheet with zero debt and $186.7M in cash. However, net income declined 24.6% despite strong revenue growth and massive EPS dilution (783%) suggests significant share issuance, indicating the company is investing heavily for growth at the expense of near-term profitability, a strategy requiring monitoring to ensure returns materialize.
Exceptional top-line growth and very high gross margins point to strong unit economics, and cash generation is healthy with positive operating cash flow and minimal capex despite zero debt. However, GAAP profitability is deeply negative with worsening EPS and extreme negative returns on capital, leaving the path to sustainable operating leverage uncertain. Maintain a neutral stance while watching for margin improvement and quality of cash flow.
Why Buy Hinge Health, Inc. Stock? HNGE Key Strengths
- Exceptional revenue growth of 50.6% YoY in services sector
- World-class gross margin of 84.6% demonstrating strong pricing power and operational efficiency
- Strong free cash flow of $43M with 23.6% FCF margin despite minimal capital expenditure, showing business generates cash despite earnings decline
- Pristine balance sheet with zero long-term debt and $186.7M in cash equivalents providing significant financial flexibility
- Strong return on equity of 31.5% despite near-term profitability headwinds
- Rapid revenue growth (+50.6% YoY)
- High gross margin (79.6%) indicating strong unit economics
- Positive OCF and FCF with no debt and solid liquidity
HNGE Stock Risks: Hinge Health, Inc. Investment Risks
- Net income declined 24.6% despite 50.6% revenue growth, indicating significant margin compression or rapidly rising operating costs unsustainable at current levels
- Massive EPS dilution of 783% YoY reflects substantial share issuance, likely from equity-based compensation or capital raises, creating ongoing shareholder dilution risk
- Operating margin of only 17.6% relative to 84.6% gross margin reveals elevated operating expense structure that must compress or revenues must grow to offset it
- Moderate current ratio of 1.30x and quick ratio of 1.27x suggest adequate but not robust short-term liquidity relative to growth investments
- Profitability trajectory requires reversal - continued net income declines despite revenue growth suggests either unsustainable operating model or temporarily depressed results
- Severely negative operating and net margins with worsening EPS
- FCF may rely on working-capital dynamics and non-cash addbacks (e.g., SBC)
- Negative ROE/ROA and small equity base raise dilution risk if cash weakens
Key Metrics to Watch
- Operating margin trend and operating expense ratio relative to revenue - must stabilize or decline as percentage of sales
- Share dilution rate and equity-based compensation costs going forward
- Net income growth relative to revenue growth - inflection point where net income resumes growth is critical
- Customer acquisition cost, lifetime value, and retention rates as indicators of growth sustainability
- Free cash flow stability and conversion rate relative to net income
- Operating margin (GAAP)
- Operating cash flow margin (OCF/Revenue)
Hinge Health, Inc. (HNGE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 23.6% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
HNGE Profit Margin, ROE & Profitability Analysis
HNGE vs Technology Sector: How Hinge Health, Inc. Compares
How Hinge Health, Inc. compares to Technology sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Hinge Health, Inc. Stock Overvalued? HNGE Valuation Analysis 2026
Based on fundamental analysis, Hinge Health, Inc. appears fundamentally strong relative to the Technology sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Hinge Health, Inc. Balance Sheet: HNGE Debt, Cash & Liquidity
HNGE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Hinge Health, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-8.31 indicates the company is currently unprofitable.
HNGE Revenue Growth, EPS Growth & YoY Performance
HNGE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $123.8M | $17.1M | $0.41 |
| Q3 2025 | $100.6M | $341.0K | $0.01 |
| Q2 2025 | $89.8M | -$12.9M | $-0.96 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Hinge Health, Inc. Dividends, Buybacks & Capital Allocation
HNGE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Hinge Health, Inc. (CIK: 0001673743)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 21, 2026 | 4 | xslF345X06/form4-05212026_080531.xml | View → |
| May 19, 2026 | 4 | xslF345X06/form4-05202026_010532.xml | View → |
| May 19, 2026 | 4 | xslF345X06/form4-05202026_010516.xml | View → |
| May 12, 2026 | 4 | xslF345X06/form4-05122026_080552.xml | View → |
| May 11, 2026 | 4 | xslF345X06/ownership.xml | View → |
❓ Frequently Asked Questions about HNGE
What is the AI rating for HNGE?
Hinge Health, Inc. (HNGE) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (HOLD) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HNGE's key strengths?
Claude: Exceptional revenue growth of 50.6% YoY in services sector. World-class gross margin of 84.6% demonstrating strong pricing power and operational efficiency. ChatGPT: Rapid revenue growth (+50.6% YoY). High gross margin (79.6%) indicating strong unit economics.
What are the risks of investing in HNGE?
Claude: Net income declined 24.6% despite 50.6% revenue growth, indicating significant margin compression or rapidly rising operating costs unsustainable at current levels. Massive EPS dilution of 783% YoY reflects substantial share issuance, likely from equity-based compensation or capital raises, creating ongoing shareholder dilution risk. ChatGPT: Severely negative operating and net margins with worsening EPS. FCF may rely on working-capital dynamics and non-cash addbacks (e.g., SBC).
What is HNGE's revenue and growth?
Hinge Health, Inc. reported revenue of $182.3M.
Does HNGE pay dividends?
Hinge Health, Inc. does not currently pay dividends.
Where can I find HNGE SEC filings?
Official SEC filings for Hinge Health, Inc. (CIK: 0001673743) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HNGE's EPS?
Hinge Health, Inc. has a diluted EPS of $0.41.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HNGE a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Hinge Health, Inc. has a BUY rating with 68% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is HNGE stock overvalued or undervalued?
Valuation metrics for HNGE: ROE of 31.5% (sector avg: 22%), net margin of 19.3% (sector avg: 18%). Higher ROE suggests strong returns relative to peers.
Should I buy HNGE stock in 2026?
Our dual AI analysis gives Hinge Health, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is HNGE's free cash flow?
Hinge Health, Inc.'s operating cash flow is $43.1M, with capital expenditures of $83.0K. FCF margin is 23.6%.
How does HNGE compare to other Technology stocks?
Vs Technology sector averages: Net margin 19.3% (avg: 18%), ROE 31.5% (avg: 22%), current ratio 1.30 (avg: 2.5).
Why is HNGE's return on equity (ROE) so high?
Hinge Health, Inc. has a return on equity of 31.5%, significantly above the Technology sector average of 22%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 19.3% net margin.